The FDA has received 4,798 adverse event reports for cats that name Velagliflozin.
- 4,798 reports name Velagliflozin in cats, which is 3.2% of all 151,164 cat reports. A report counts under every active ingredient it names.
- 16% are marked serious and 8.0% record a death or euthanasia; across all cat reports those figures are 27% and 9.4%.
- 26% are complaints that the product did not work (19% across all cat reports).
- The clinical signs reported most are ketosis, lack of efficacy and weight loss.
- The FDA lists 1 approved animal drug application containing Velagliflozin for cats, the earliest approved in 2023.
- None of this is a rate. The FDA data does not record how many cats were given Velagliflozin, so it cannot say how often any of this happens.
How the reports break down
| What the reports say | Reports | Share of this medicine's reports | All cat reports |
|---|---|---|---|
| Marked seriousthe FDA record flags the report as serious | 786 | 16% | 27% |
| Death or euthanasiathe outcome recorded in the report, with no finding of cause | 383 | 8.0% | 9.4% |
| Did not worka complaint that the product failed to work, which the FDA files as an adverse event | 1,250 | 26% | 19% |
| Seizurea seizure or convulsion is among the clinical signs | 18 | 0.4% | 2.6% |
| Not used per labelthe report says the product was not used the way its label directs | 1,463 | 30% | 33% |
Where on the body do the reported signs sit?
Not on the body: Did not work 12% Whole body 8.9%
- Blood and organ tests40%ketosis, ketonuria, elevated blood urea nitrogen (bun), hypokalaemia and 8 more
- Stomach and gut32%weight loss, diarrhoea, vomiting, anorexia and 2 more
- Did not work12%lack of efficacy
- Whole body8.9%lethargy, death by euthanasia
- Thirst and urination6.7%dehydration, urinary tract infection, polydipsia, polyuria
Each figure is a share of sign mentions among the 25 signs reported most for Velagliflozin in cats. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.
Clinical signs reported most
- Ketosis1,741 36%
- Lack of efficacy1,222 25%
- Weight loss1,169 24%
- Diarrhoea760 16%
- Vomiting672 14%
- Lethargy623 13%
- Ketonuria574 12%
- Anorexia443 9.2%
Reports received per year
Is it approved for cats?
The FDA lists 1 approved animal drug application containing Velagliflozin for cats, the earliest approved in 2023.
| Product | Form | Approved for | First approved | FDA application |
|---|---|---|---|---|
| SenvelgoBoehringer lngelheim Animal Health USA, Inc. | Solution RX | Cat | 2023 | 141-568 |
What can you do next?
Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.
Where can you go from this result?
This result is one of 94 in the lookup. Open it in the lookup to set it beside another medicine, or read how the counts were collected.
- Bexagliflozin in cats4,053
- Ketamine in cats4,012
- Buprenorphine in cats5,611
- Emodepside in cats5,732
To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.
Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.